Recursion biotech market cap
WebApr 16, 2024 · SALT LAKE CITY, April 16, 2024 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its … WebJun 30, 2024 · These indices determine membership primarily by objective, market-capitalization rankings and style attributes. About Recursion Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning, and engineering.
Recursion biotech market cap
Did you know?
WebAs of March 2024 Recursion Pharmaceuticals has a market cap of $1.29 Billion . This makes Recursion Pharmaceuticals the world's 4303th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly … WebMarket capitalization of Recursion Pharmaceuticals (RXRX) Market cap: $1.29 Billion As of March 2024 Recursion Pharmaceuticals has a market cap of $1.29 Billion . This makes …
WebRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. About the company RXRX fundamental analysis Rewards WebApr 12, 2024 · April 12, 2024 Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for various indications, announced terms for its IPO on Monday. The Salt Lake City, UT-based company plans to raise $306 million by offering 18 million shares at a price range of $16 to $18.
WebApr 6, 2024 · Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis. WebRecursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
WebApr 16, 2024 · Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the …
WebApr 10, 2024 · RXRX’s market cap is 1.25 Bil. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. melinda o\\u0027rourke ophthalmologistWebBased on the recorded statements, the market capitalization of Recursion Pharmaceuticals is about 1.45 B. This is 88.81% lower than that of the Healthcare sector and 69.45% lower than that of the Biotechnologyindustry. The market capitalization for all United States stocks is 92.39% higher than that of the company. melinda on dated and relatedWebApr 10, 2024 · Recursion Pharmaceuticals (Nasdaq:RXRX) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech Recursion … narrow stone coffee tableWebMar 17, 2024 · SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to … melinda owens law firm granbury txWebAll financial data provided by Standard & Poor's Capital IQ. Data Last Updated (UTC time) Company Analysis: 2024/03/19 00:00: End of Day Share Price melinda on match game 75WebRecursion Pharmaceuticals ramped up its IPO target from $100 million to $306 million earlier this week, but the artificial intelligence biotech is scratching that plan. melinda on facebookWebJul 2, 2024 · Before entering the public markets this spring, Recursion had attracted over $460 million in venture investments, according to tech data aggregator Crunchbase. At … melinda on the map